Developer docs
API playgroundTry for free, no card

Search company profiles

dr max pharma

Full company profile

uuid02m44ja

Namestring
dr max pharma
Legal namestring
Dr. Max Pharma s.r.o.
Websiteurl
drmaxpharma.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Dr. Max Pharma s.r.o. is a Czech private-label pharmaceutical manufacturer and product development company headquartered in Prague, founded in 2011 and wholly owned by Penta Investments through the Dr. Max Group. The company develops and supplies an own-brand portfolio of more than 1,340 SKUs across five categories: food supplements (53.8% of portfolio), OTC medicines (15.2%), medical devices (15.9%), cosmetics (6.6%), and prescription pharmaceuticals (5.7%). Distribution is exclusively through the affiliated Dr. Max pharmacy chain, which operates 3,005 pharmacies across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) and accounts for 300,000 units sold daily as of 2024.

The company collaborates with more than 400 global suppliers, primarily in Europe and Asia, and holds proprietary brand identities including BEBELO (baby care, launched 2020), Nuance (luxury cosmetics, launched 2015), PRO32, MaxMobility, and the Medreg generic RX range. Dr. Max Pharma obtained Good Manufacturing Practice (GMP) certification in 2024, establishing compliance with European pharmaceutical manufacturing standards across multi-market product registration and pharmacovigilance systems. The company was ranked No. 1 producer in Czech Republic pharmaceutical retail by IQVIA in 2023.

The business model is a vertically integrated private-label operation: Dr. Max Pharma develops, sources, and supplies own-brand products that are sold exclusively through its sister pharmacy chain under common Penta Investments ownership. Revenue is captured at the wholesale/manufacturing level rather than retail, with no disclosed third-party customers. A merger with sister company Medreg was initiated on May 18, 2026, with an effective date of January 1, 2027, intended to consolidate generic RX operations within the group.

Short descriptiontext

Dr. Max Pharma is a Prague-based private-label pharmaceutical manufacturer, wholly owned by Penta Investments, that develops and supplies over 1,340 own-brand SKUs (supplements, OTC, devices, cosmetics, RX drugs) exclusively to the 3,005-pharmacy Dr. Max chain across six European countries.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersPrague, Czechia
HQ citystring
Prague
HQ countrystring
Czechia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private label pharmaceuticals, OTC medicines, food supplements, medical devices, generic prescription drugs
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Private-label pharmaceutical manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Label Pharmaceutical Product Sales
TypeOne Time License
Description

Dr. Max Pharma generates revenue by developing and supplying private-label pharmaceutical and health products (OTC medicines, food supplements, medical devices, cosmetics, RX drugs) to the Dr. Max pharmacy chain across six European countries. Products are sold under owned brands including BEBELO (baby care), Nuance (cosmetics), PRO32, and MaxMobility. The company collaborates with over 400 suppliers worldwide to manufacture products that are distributed exclusively through Dr. Max retail pharmacies and e-commerce platforms.

drmaxpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1BEBELO
Description

Exclusive brand for the complete care of mothers and babies, including baby and toddler formula, diapers and gentle baby cosmetics.

drmaxpharma.com
+4 more records
Core offering1 text field

Dr. Max Pharma develops and manufactures private-label pharmaceutical and healthcare products — including food supplements, OTC medicines, medical devices, cosmetics, and RX prescription drugs — under proprietary brands such as BEBELO, Nuance, PRO32, MaxMobility, and Medreg. The company operates as the product development and sourcing arm of the Dr. Max pharmacy chain, distributing exclusively through Dr. Max retail pharmacies and e-commerce platforms across six European countries (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 300,000 units sold daily
+3 more records
Product overview1 text field

Dr. Max Pharma is a pharmaceutical company and private-label product manufacturer for the Dr. Max pharmacy chain, operating as the pioneer of successful private label projects in Central Europe. The company offers a diversified portfolio exceeding 1,340 SKUs across multiple product categories: Food Supplements (53.8%) including vitamins and minerals; OTC medicines (15.2%) like ibuprofen and paracetamol; Medical Devices (15.9%) including nasal sprays and lozenges; Cosmetics (6.6%) including the Nuance luxury brand; and Prescription (RX) pharmaceuticals (5.7%) under the Medreg brand. Specialized sub-brands include BEBELO® for baby care, PRO32, and MaxMobility. The products are sold across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) through Dr. Max pharmacies and other retail channels.

Product and service3 records
1Food Supplements
CategoryFood Supplements
Description

Vitamins, minerals, and dietary supplements that support everyday health and wellness, comprising 53.8% of the product portfolio. Targeted at consumers seeking preventive health, nutritional support, and immune system maintenance.

2OTC (Over-the-Counter Medicines)
CategoryOTC Medicines
Description

Non-prescription medications including pain relievers (Ibuprofen, Paracetamol, Diclofenac), respiratory treatments (Acetylcystein, Ambroxol), and allergy relief (Cetirizin), representing 15.2% of the portfolio. Designed for consumers seeking self-medication options for common ailments.

3Medical Devices
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1A&D Pharma
Strategic tierMajorTypeOthersAnnounced on2019-01-01
Description

Dr. Max Group completed its largest acquisition in history - the takeover of A&D Pharma in 2019. This acquisition enabled the launch of extensive private label portfolio in Romania, expanding Dr. Max Pharma's market presence significantly in that country.

drmaxpharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Strategic partnership with Medreg to expand portfolio to include RX/generic drugs, boosting market strength. First registered products under this partnership include Alergimed (Poland) and Sildenafil Medreg (Slovakia) in 2016. The partnership enabled Dr. Max Pharma to enter the prescription pharmaceutical market.

Strategic tierCoreTypeOthers
Description

Dr. Max Pharma is a proud member of the Dr. Max Group, operating as the pharmaceutical manufacturing and private label product development arm. The company supplies own-brand products exclusively to the Dr. Max pharmacy chain across six European countries. The Dr. Max Group includes over 3,000 pharmacies and is a major pharmaceutical retail operator in Central and Eastern Europe.

Strategic tierMajorTypeOthers
Description

Dr. Max Pharma collaborates with over 400 suppliers worldwide, particularly in Europe and Asia. Suppliers are carefully selected to ensure quality ingredients and products, with focus on quality, innovation, and sustainability. Long-term, transparent partnerships with suppliers support the company's goal of providing accessible healthcare.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Apotex is one of Canada's largest generic pharmaceutical manufacturers with growing European presence, producing generic RX, OTC, and consumer health products — comparable in private-label generics manufacturing model.

TypeDirect peer
Description

Perrigo is the world's largest manufacturer of private-label over-the-counter and generic pharmaceuticals, supplying retailer-owned brands across Europe and globally — the closest functional analog to Dr. Max Pharma's private-label model for a pharmacy chain.

TypeDirect peer
Description

Medreich is a contract and private-label pharmaceutical manufacturer supplying OTC and generic products to European retail and pharmacy chains — directly comparable as a private-label contract manufacturer serving pharmacy customers.

TypeDirect peer
Description

STADA is a European-focused generic and consumer healthcare company producing private-label and branded generics, OTC medicines, and food supplements across multiple European markets — directly comparable in geography and product mix.

TypeBroad incumbent
Description

Viatris is a global pharmaceutical company with an extensive generics and OTC portfolio serving European retail pharmacy channels — comparable in product range and channel focus but as a broad incumbent.

6Sandoz Group
TypeBroad incumbent
Description

Sandoz, spun off from Novartis, is a global leader in generics and biosimilars with significant European manufacturing — comparable in product categories (generics, OTC, specialty pharma) but operates at much larger scale and breadth.

TypeEmerging player
Description

Dr. Reddy's is a global pharmaceutical manufacturer with growing European OTC and generics presence, particularly through acquisitions — comparable in generic and OTC manufacturing but with a different geographic anchor.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with a broad European portfolio across OTC and RX generics — comparable product categories and scale, but operates as a broad incumbent rather than a private-label specialist.

TypeDirect peer
Description

Omega Pharma is a major European OTC and personal care manufacturer owned by Perrigo, producing private-label and brand-equivalent products sold through European pharmacy channels — comparable business model and channel.

TypeDirect peer
Description

Zentiva is a European generic pharmaceutical manufacturer with strong presence in Central and Eastern Europe, producing branded generics, OTC, and consumer health products — overlaps directly with Dr. Max Pharma's CEE-focused portfolio strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

dr max pharma

Private-label pharmaceutical manufacturingdrmaxpharma.com

Dr. Max Pharma is a Prague-based private-label pharmaceutical manufacturer, wholly owned by Penta Investments, that develops and supplies over 1,340 own-brand SKUs (supplements, OTC, devices, cosmetics, RX drugs) exclusively to the 3,005-pharmacy Dr. Max chain across six European countries.

What dr max pharma does

Dr. Max Pharma s.r.o. is a Czech private-label pharmaceutical manufacturer and product development company headquartered in Prague, founded in 2011 and wholly owned by Penta Investments through the Dr. Max Group. The company develops and supplies an own-brand portfolio of more than 1,340 SKUs across five categories: food supplements (53.8% of portfolio), OTC medicines (15.2%), medical devices (15.9%), cosmetics (6.6%), and prescription pharmaceuticals (5.7%). Distribution is exclusively through the affiliated Dr. Max pharmacy chain, which operates 3,005 pharmacies across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) and accounts for 300,000 units sold daily as of 2024.

The company collaborates with more than 400 global suppliers, primarily in Europe and Asia, and holds proprietary brand identities including BEBELO (baby care, launched 2020), Nuance (luxury cosmetics, launched 2015), PRO32, MaxMobility, and the Medreg generic RX range. Dr. Max Pharma obtained Good Manufacturing Practice (GMP) certification in 2024, establishing compliance with European pharmaceutical manufacturing standards across multi-market product registration and pharmacovigilance systems. The company was ranked No. 1 producer in Czech Republic pharmaceutical retail by IQVIA in 2023.

The business model is a vertically integrated private-label operation: Dr. Max Pharma develops, sources, and supplies own-brand products that are sold exclusively through its sister pharmacy chain under common Penta Investments ownership. Revenue is captured at the wholesale/manufacturing level rather than retail, with no disclosed third-party customers. A merger with sister company Medreg was initiated on May 18, 2026, with an effective date of January 1, 2027, intended to consolidate generic RX operations within the group.

dr max pharma firmographics

Firmographics
Name
dr max pharma
Legal name
Dr. Max Pharma s.r.o.
Website
https://drmaxpharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Short description
Dr. Max Pharma is a Prague-based private-label pharmaceutical manufacturer, wholly owned by Penta Investments, that develops and supplies over 1,340 own-brand SKUs (supplements, OTC, devices, cosmetics, RX drugs) exclusively to the 3,005-pharmacy Dr. Max chain across six European countries.
Ownership category
akta.pro rank

dr max pharma industry classification

Industry
Product category
Private-label pharmaceutical manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Private label pharmaceuticals
  • OTC medicines
  • Food supplements
  • Medical devices
  • Generic prescription drugs

Where dr max pharma is headquartered

Location

Headquarters

HQ city
Prague
HQ country
Czechia
HQ region
Europe

Offices2 records

Markets served

dr max pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Private Label Pharmaceutical Product Sales: Dr. Max Pharma generates revenue by developing and supplying private-label pharmaceutical and health products (OTC medicines, food supplements, medical devices, cosmetics, RX drugs) to the Dr. Max pharmacy chain across six European countries. Products are sold under owned brands including BEBELO (baby care), Nuance (cosmetics), PRO32, and MaxMobility. The company collaborates with over 400 suppliers worldwide to manufacture products that are distributed exclusively through Dr. Max retail pharmacies and e-commerce platforms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

dr max pharma product offering

Product offering

Core offering

Dr. Max Pharma develops and manufactures private-label pharmaceutical and healthcare products — including food supplements, OTC medicines, medical devices, cosmetics, and RX prescription drugs — under proprietary brands such as BEBELO, Nuance, PRO32, MaxMobility, and Medreg. The company operates as the product development and sourcing arm of the Dr. Max pharmacy chain, distributing exclusively through Dr. Max retail pharmacies and e-commerce platforms across six European countries (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia).

Product overview

Dr. Max Pharma is a pharmaceutical company and private-label product manufacturer for the Dr. Max pharmacy chain, operating as the pioneer of successful private label projects in Central Europe. The company offers a diversified portfolio exceeding 1,340 SKUs across multiple product categories: Food Supplements (53.8%) including vitamins and minerals; OTC medicines (15.2%) like ibuprofen and paracetamol; Medical Devices (15.9%) including nasal sprays and lozenges; Cosmetics (6.6%) including the Nuance luxury brand; and Prescription (RX) pharmaceuticals (5.7%) under the Medreg brand. Specialized sub-brands include BEBELO® for baby care, PRO32, and MaxMobility. The products are sold across six European markets (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia) through Dr. Max pharmacies and other retail channels.

Differentiator

Problem solved

Functional benefit

Brands

  • BEBELO: Exclusive brand for the complete care of mothers and babies, including baby and toddler formula, diapers and gentle baby cosmetics.
  • Nuance
  • PRO32
  • MaxMobility
  • Medreg

Products and services

  • Food Supplements Vitamins, minerals, and dietary supplements that support everyday health and wellness, comprising 53.8% of the product portfolio. Targeted at consumers seeking preventive health, nutritional support, and immune system maintenance.
  • OTC (Over-the-Counter Medicines) Non-prescription medications including pain relievers (Ibuprofen, Paracetamol, Diclofenac), respiratory treatments (Acetylcystein, Ambroxol), and allergy relief (Cetirizin), representing 15.2% of the portfolio. Designed for consumers seeking self-medication options for common ailments.
  • Medical Devices

Quantifiable outcome

  • 300,000 units sold daily
  • +3 more outcomes

Companies that use dr max pharma

Customer profile

Named customers7 records

Segments7 records

Ideal customer profiles2 records

dr max pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

dr max pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • A&D PharmamajorOthers · 1 January 2019Dr. Max Group completed its largest acquisition in history - the takeover of A&D Pharma in 2019. This acquisition enabled the launch of extensive private label portfolio in Romania, expanding Dr. Max Pharma's market presence significantly in that country.
  • MedregcoreStrategic or Co-development Partner · 1 January 2016Strategic partnership with Medreg to expand portfolio to include RX/generic drugs, boosting market strength. First registered products under this partnership include Alergimed (Poland) and Sildenafil Medreg (Slovakia) in 2016. The partnership enabled Dr. Max Pharma to enter the prescription pharmaceutical market.
  • Dr. Max GroupcoreOthersDr. Max Pharma is a proud member of the Dr. Max Group, operating as the pharmaceutical manufacturing and private label product development arm. The company supplies own-brand products exclusively to the Dr. Max pharmacy chain across six European countries. The Dr. Max Group includes over 3,000 pharmacies and is a major pharmaceutical retail operator in Central and Eastern Europe.
  • Global Pharmaceutical Suppliers (400+)majorOthersDr. Max Pharma collaborates with over 400 suppliers worldwide, particularly in Europe and Asia. Suppliers are carefully selected to ensure quality ingredients and products, with focus on quality, innovation, and sustainability. Long-term, transparent partnerships with suppliers support the company's goal of providing accessible healthcare.

Scale indicators7 records

Recent moves4 records

Expansion highlights5 records

dr max pharma competitors and assessment

Company assessment

Emerging players

  • Apotex: Apotex is one of Canada's largest generic pharmaceutical manufacturers with growing European presence, producing generic RX, OTC, and consumer health products — comparable in private-label generics manufacturing model.
  • Dr. Reddy's Laboratories: Dr. Reddy's is a global pharmaceutical manufacturer with growing European OTC and generics presence, particularly through acquisitions — comparable in generic and OTC manufacturing but with a different geographic anchor.

Direct peers

  • Perrigo Company: Perrigo is the world's largest manufacturer of private-label over-the-counter and generic pharmaceuticals, supplying retailer-owned brands across Europe and globally — the closest functional analog to Dr. Max Pharma's private-label model for a pharmacy chain.
  • Medreich (formerly part of Cipla): Medreich is a contract and private-label pharmaceutical manufacturer supplying OTC and generic products to European retail and pharmacy chains — directly comparable as a private-label contract manufacturer serving pharmacy customers.
  • STADA Arzneimittel: STADA is a European-focused generic and consumer healthcare company producing private-label and branded generics, OTC medicines, and food supplements across multiple European markets — directly comparable in geography and product mix.
  • Omega Pharma (Perrigo subsidiary): Omega Pharma is a major European OTC and personal care manufacturer owned by Perrigo, producing private-label and brand-equivalent products sold through European pharmacy channels — comparable business model and channel.
  • Zentiva Group: Zentiva is a European generic pharmaceutical manufacturer with strong presence in Central and Eastern Europe, producing branded generics, OTC, and consumer health products — overlaps directly with Dr. Max Pharma's CEE-focused portfolio strategy.

Broad incumbents

  • Viatris (Mylan + Upjohn): Viatris is a global pharmaceutical company with an extensive generics and OTC portfolio serving European retail pharmacy channels — comparable in product range and channel focus but as a broad incumbent.
  • Sandoz Group: Sandoz, spun off from Novartis, is a global leader in generics and biosimilars with significant European manufacturing — comparable in product categories (generics, OTC, specialty pharma) but operates at much larger scale and breadth.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a broad European portfolio across OTC and RX generics — comparable product categories and scale, but operates as a broad incumbent rather than a private-label specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

dr max pharma compliance and trust

Trust signal

Compliance3 records

dr max pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

dr max pharma leadership team

Management profile

Number of profiles

Profiles6 records

dr max pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

dr max pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about dr max pharma

What does dr max pharma do?

Dr. Max Pharma develops and manufactures private-label pharmaceutical and healthcare products — including food supplements, OTC medicines, medical devices, cosmetics, and RX prescription drugs — under proprietary brands such as BEBELO, Nuance, PRO32, MaxMobility, and Medreg. The company operates as the product development and sourcing arm of the Dr. Max pharmacy chain, distributing exclusively through Dr. Max retail pharmacies and e-commerce platforms across six European countries (Czech Republic, Romania, Italy, Poland, Slovakia, Serbia).

Is dr max pharma a public or private company?

dr max pharma is a private company. It is classified as private equity controlled and is currently operating.

When was dr max pharma founded?

dr max pharma was founded in 2011.

Where is dr max pharma based?

dr max pharma is headquartered in Prague, Czechia, in the Europe region.

How does dr max pharma make money?

One revenue line is on record: private Label Pharmaceutical Product Sales.

Who are dr max pharma's main competitors?

Emerging players on record are Apotex and Dr. Reddy's Laboratories. Direct peers are Perrigo Company, Medreich (formerly part of Cipla), STADA Arzneimittel, Omega Pharma (Perrigo subsidiary) and Zentiva Group. Broad incumbents are Viatris (Mylan + Upjohn), Sandoz Group and Teva Pharmaceutical Industries.

Does dr max pharma have an API?

No public API is recorded for dr max pharma.

What industry is dr max pharma in?

dr max pharma's product category is Private-label pharmaceutical manufacturing. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales